ArticleCancers2022

Utilization of Cancer Cell Line Screening to Elucidate the Anticancer Activity and Biological Pathways Related to the Ruthenium-Based Therapeutic BOLD-100.

Brian J Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.